AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06449781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutetium (177Lu) vipivotide tetraxetan
Description: The intervention will consist of a single administration of 7,4 GBq of lutetium (177Lu) vipivotide tetraxetan
Study NCT06462690 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pre-mid-post test
Description: (PIF) (DLQI) (GCS) Data Collection Forms Humidity measurement with DMM device
Study NCT06176027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacytidine plus CAOLD regimen
Description: Patients were treated by Azacytidine(75 mg/m2 on days 1-7) plus CAOLD regimen (cyclophosphamide 400mg/m2 qd d1; cytarabine 30mg/m2 qd d1-d4; vindesine 2mg/m2 qd d1; pegaspargase 2500iu/m2 qd d2; dexamethasone 7.5mg/m2 qd d1-d5)
Study NCT06050408 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1hz repetitive transcranial magnetic stimulation
Description: 1hz rTMS applied over P3 EEG 10-20 location. Total of 1200 pulses administered. Figure of eight coil used to stimulate, held tangential to the scalp.
Study NCT05457309 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: malignant fungating wounds care regimen
Description: 1) Preliminary construction of regimen: The researchers summarized the literatures and guidelines about malignant fungating wounds care, and then formed a preliminary draft of the regimen.2) Expert consultation: Experts in malignant fungating wound care, breast cancer and rehabilitation were consulted by email, and the researchers revised the protocol according to the experts' comments, and the final draft was determined after multiple rounds of consultation with experts. 3) Pre-experiment: The researchers investigated the enrolled patients to assess the feasibility of the protocol, and adjusted the content based on the feedback.4) Final Determining: including health records establishment, the intervention time, implementers, location, method and frequency. A wound care team was formed, interventions were carried out in terms of somatic care, wound home care, psychological support, and rehabilitation guidance, and the enrolled patients would be regularly followed by the researchers.
Study NCT05459870 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4SCAR T cells
Description: Infusion of 4SCAR T cells at 10\^6 cells/kg body weight via IV
Study NCT05430789 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 5As brief advice
Description: Participants will receive brief face-to-face advice following a 5As model at baseline:~1. Ask: Smoking patients will be asked about their smoking status.~2. Advise: Smoking patients will be advised to quit in a clear and personalised manner, with a focus on smoking-related diseases.~3. Assess: Smoking patients will be assessed for their readiness to quit by assessing their self-efficacy and perceived importance.~4. Assist: Those who are ready to quit will be assisted in setting a quit plan.~5. Arrange: Refer to smoking cessation services.
Study NCT05430789 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 5As brief advice
Description: Participants will receive brief face-to-face advice following a 5As model at baseline:~1. Ask: Smoking patients will be asked about their smoking status.~2. Advise: Smoking patients will be advised to quit in a clear and personalised manner, with a focus on smoking-related diseases.~3. Assess: Smoking patients will be assessed for their readiness to quit by assessing their self-efficacy and perceived importance.~4. Assist: Those who are ready to quit will be assisted in setting a quit plan.~5. Arrange: Refer to smoking cessation services.
Study NCT05430789 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-help e-booklet
Description: A 12-page generic self-help smoking cessation e-booklet via IM apps, including:~1. Highlights of the absolute risk of death due to smoking;~2. Smoking and diseases management;~3. Ten horrible pictorial warnings of health consequences of smoking and second-hand smoking;~4. Benefits of quitting;~5. Methods to quit and handle. withdrawal symptoms.
Study NCT05430789 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-help e-booklet
Description: A 12-page generic self-help smoking cessation e-booklet via IM apps, including:~1. Highlights of the absolute risk of death due to smoking;~2. Smoking and diseases management;~3. Ten horrible pictorial warnings of health consequences of smoking and second-hand smoking;~4. Benefits of quitting;~5. Methods to quit and handle. withdrawal symptoms.
Study NCT05430789 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse-led mHealth intervention
Description: Participants will receive real-time mHealth behaviour and psychosocial support for 12 weeks after baseline through IM apps. mHealth intervention consists of two main parts: regular instant messaging on smoking cessation and personalized real-time mHealth chatting on smoking and disease (including active referral to smoking cessation service)
Study NCT05430789 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Regular intervention
Description: Participants will receive text messages using IM app with content on general health and reminding the importance of participating in the follow-up surveys and biochemical validation for quitting.
Study NCT05617846 — intervention group
Intervention type: OTHER
Intervention: Anti-osteoporosis therapy
Description: Bone healing, limb function, and complications of postoperative osteolysis in patients with bone tumors of the extremities treated with anti-osteoporosis therapy.
Study NCT05388890 — intervention group
Intervention type: DRUG
Intervention: MLD
Description: Modified Liujunzi Decoction is provided by the chinese pharmacy of Peking University First Hospital , one dose per day, taken in twice, and the course of treatment is 6 months.
Study NCT05388890 — intervention group
Intervention type: DRUG
Intervention: WFC
Description: Chinese patent medicine, take according to the instructions, the course of treatment is 6 months.
Study NCT05668793 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: GNB4 and Riplet Gene Methylation Combined Detection Kit (Fluorescent PCR Method)
Description: Blood samples from participants in the group were collected and methylation tests were performed according to the kit instructions.
Study NCT05443477 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hericium Erinaceus Mycelium
Description: participants received two oral capsules containing Hericium erinaceus Mycelium every day for the 3 months.
Study NCT05443477 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: participants received two oral capsules containing Probiotic powder every day for the 3 months.
Study NCT05443477 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: participants received two oral capsules containing control powder every day for the 3 months.
Study NCT06236035 — intervention group
Intervention type: DEVICE
Intervention: Analgesia nociception index
Description: a device to assess patient's pain during surgery
Study NCT05718505 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Atmo Motility Gas Capsule System
Description: The Atmo System measures whole gut and regional gut transit times. Measurements of GI tract transit times are used for evaluating motility disorders.~Gastric emptying time (GET) is indicated for the evaluation of patients with suspected gastroparesis. Delayed GET is implicated in such disorders as idiopathic and diabetic gastroparesis and functional non-ulcer dyspepsia.~Colonic transit time (CTT) is indicated for the evaluation of colonic transit in patients with chronic constipation, to aid in differentiating slow and normal transit constipation. In the case where ileocecal junction transit cannot be determined the system will report combined Small and Large Bowel Transit Time (SLBTT).~Transit times are derived from measures of temperature, relative humidity, hydrogen concentration, and carbon dioxide concentration, in conjunction with indicators of fermentation activity, capsule tumble, and antenna reflectance. Not for use in pediatric patients.
Study NCT05718505 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SmartPill Monitoring System
Description: The SmartPill GI Monitoring System (Medtronic) offers a method for measuring gastric emptying time (GET), small bowel transit time (SBTT), colonic transit time (CTT), small bowel large bowel transit time (SLBTT) and whole gut transit time (WGTT) with a single test, which can be used as an aid for the diagnosis of both gastroparesis and slow transit constipation.~The SmartPill System measures pH, temperature and pressure. It is approved for use in the measurement of GI transit times by the FDA.
Study NCT06702150 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Changing the nursing care model to the primary nursing model
Description: The nurses received training in primary nursing care before the start of the intervention. The model was tested and implemented in early April 2022. Since then, all patients admitted to the unit have been assigned to a primary nurse within the first 48 hours. This nurse is responsible for developing and monitoring the patient's care plan, assessing care needs, implementing the care plan and evaluating the outcomes. This nurse is also responsible for coordinating care needs and discharge planning with other healthcare professionals. When the primary nurse is not working, another nurse from his or her team continues the care plan that he or she has defined. All patients admitted to the unit who met the selection criteria were informed about the study and, if they agreed to take part, completed a self-care competence questionnaire at admission (baseline), at discharge and one month after discharge. They also completed a questionnaire on satisfaction with nursing care at discharge.
Study NCT05843695 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iTCBT-I
Description: Individual format over 2 weeks
Study NCT04865887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200mg, every 3 weeks, IV infusion
Study NCT04865887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 20 mg (2 capsules x10mg), daily, orally
Study NCT05959564 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Chatbot Intervention
Description: In this intervention, participants will first see a standard CDC HPV vaccine message. After that they will be invited to interact with a chatbot designed to deliver additional HPV vaccine messages, which are tailored to their personalities.
Study NCT05959564 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-Personalized Chatbot Intervention
Description: In this intervention, participants will first see a standard CDC HPV vaccine message. After that they will be invited to interact with a chatbot designed to deliver additional HPV vaccine messages, which are not tailored to their personalities.
Study NCT05959564 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No Chatbot Control
Description: In this intervention, participants will see a standard CDC HPV vaccine message only and will not interact with any chatbot.
Study NCT05758246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fisetin-dose 1
Description: 20mg/kg once a day for one day.
Study NCT05758246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fisetin-dose 2
Description: 20mg/kg once a day for two days
Study NCT05758246 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo treatment
Study NCT06353113 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Down Dog Prenatal Yoga App
Description: The Down Dog prenatal yoga app launched in 2015 and was designed to align with the changes a pregnant body goes through in each trimester. Users can select a practice by trimester, which will offer modification cues to work with a changing body during pregnancy. Users can also customize their experience by boosting things like Heartburn or Pubic Symphysis so they can continue to practice yoga and omit poses that might be uncomfortable. The app also utilizes user feedback, to continuously implement new practices to better their app for user interface.~All of the prenatal yoga classes were created by a certified and experienced prenatal yoga instructor who has a 200hr yoga certification through Pure Yoga (New York), 80hr prenatal yoga certification through Prenatal Yoga Center (New Yoga), and is Trauma Informed Yoga certified through Exhale to Inhale (New York).
Study NCT06550362 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: iron sulfate
Description: Oral iron administration
Study NCT06550362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iron sulfate
Description: Oral iron administration
Study NCT05657964 — intervention group
Intervention type: DEVICE
Intervention: Gokhale sensor
Description: Participants enrolled in the Gokhale Arm will be provided the Gokhale PostureTracker, a wearable posture monitoring sensor developed for interactive posture coaching, and a loaner smartphone with pre-installed App. Participants will be provided instruction to apply the sensor on their lumbar area and receive real-time visual feedback on their posture kinematic during the class. Participants can also perform normal daily activities while wearing the device. Data collected by the sensor will be sent to a HIPAA compliance server and shared with Stanford researchers.
Study NCT06145880 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Artificial intelligence tool for transthoracic echocardiography
Description: Pre-defined cohorts will be used to train the artificial intelligence tool for transthoracic echocardiography to improve the diagnosis of PH on TTE.
Study NCT05167396 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Retinaute (BioSerenity)
Description: Wearable device in the form of a virtual reality headset for the recording of electrophysiological measurements such as electroretinogram (ERG) and electrocenphalogram (EEG), ISCEV standards
Study NCT05167396 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG Headset 64 electrodes (BioSemi)
Description: EEG headset with 64 electrodes for the recording of visual cortical electrophysiological signals
Study NCT05167396 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MonPackOne (Metrovision)
Description: Standard device for the recording of electroretinography (ERG) measurements, ISCEV standards~WARNING : Device used only in 3 healthy controls to address the secondary objective
Study NCT04764825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: The dosage administered differ in regards to age and tolerance to opioids:~0.2 mg/kg: all patients \<65 years of age and all patients tolerant to opioids (defined as treatment with opioids (at least the last 7days) exceeding 60 oral morphine milligram equivalents daily.~0.15 mg/kg: Opioid naive patients > 65 years of age.
Study NCT04764825 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: The dosage administered differ in regards to age and tolerance to opioids:~0.2 mg/kg: all patients \<65 years of age and all patients tolerant to opioids (defined as treatment with opioids (at least the last 7days) exceeding 60 oral morphine milligram equivalents daily.~0.15 mg/kg: Opioid naive patients > 65 years of age.
Study NCT04846920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belzutifan
Description: 40 mg tablet administered orally at a dose of 160 mg, 200 mg, or 120 mg.
Study NCT05727865 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online CBT following cardiac surgery
Description: It will include psychoeducation, behavioral activation to address post-operative fatigue and depression, interoceptive exposure to reduce fear of cardiac-related symptoms and in-vivo exposure to reduce avoided situations, and activities to enhance physical activity and wellbeing. Labeling (i.e., describing post-operative and/or cardiac-related symptoms, thoughts, and feelings) will be used continuously during treatment to enhance the effect of exposure and pain management
Study NCT04369274 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation with the automated BVM compressor
Description: Mechanical ventilation is accomplished with a device that mechanically squeezes a manual bag valve instead of by hand. The rate and volume of compression are adjustable, and the device has appropriate alarms and safety features.
Study NCT05845671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amivantamab 1050mg
Description: Amivantamab is a bispecific antibody that binds to the extracellular domains of EGFR and MET.~In in vitro and in vivo studies amivantamab was able to disrupt EGFR and MET signaling functions through blocking ligand binding and, in exon 20 insertion mutation models, degradation of EGFR and MET. The presence of EGFR and MET on the surface of tumor cells also allows for targeting of these cells for destruction by immune effector cells, such as natural killer cells and macrophages, through antibody-dependent cellular cytotoxicity (ADCC) and trogocytosis mechanisms, respectively.
Study NCT05845671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amivantamab 1400mg
Description: Amivantamab is a bispecific antibody that binds to the extracellular domains of EGFR and MET.~In in vitro and in vivo studies amivantamab was able to disrupt EGFR and MET signaling functions through blocking ligand binding and, in exon 20 insertion mutation models, degradation of EGFR and MET. The presence of EGFR and MET on the surface of tumor cells also allows for targeting of these cells for destruction by immune effector cells, such as natural killer cells and macrophages, through antibody-dependent cellular cytotoxicity (ADCC) and trogocytosis mechanisms, respectively.
Study NCT05845671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amivantamab (to be determined)
Description: Amivantamab is a bispecific antibody that binds to the extracellular domains of EGFR and MET.~In in vitro and in vivo studies amivantamab was able to disrupt EGFR and MET signaling functions through blocking ligand binding and, in exon 20 insertion mutation models, degradation of EGFR and MET. The presence of EGFR and MET on the surface of tumor cells also allows for targeting of these cells for destruction by immune effector cells, such as natural killer cells and macrophages, through antibody-dependent cellular cytotoxicity (ADCC) and trogocytosis mechanisms, respectively.~Dose will be determine after the Safety Lead-In
Study NCT06123897 — intervention group
Intervention type: OTHER
Intervention: Regular follow-up assessments without intervention.
Description: Participants will undergo follow-up for a minimum of one year, with regular clinical data collection at baseline, half a month, 1st month, 3rd months, 6th months, 9th months and 12th months. Baseline assessments will include demographic information, medical history, and previous medication use. For participants on antipsychotics at baseline, the Simpson-Angus Scale for extrapyramidal symptoms(SAS) will also be administered. At baseline and each follow-up, data on current medication, physical examination, anthropometry, ECG, EEG, psychiatric scales (PANSS, CGI, GAF, PSP, SAS, TESS, MMAS-8), the MATRICS Consensus Cognitive Battery, and laboratory tests (blood routine, liver and renal function, lipids, fasting glucose, fasting insulin, HbA1c) will be obtained, alongside fMRI, eye movement, and fNIRS measures. Blood samples will be collected and stored for mechanistic investigations.
Study NCT06123897 — intervention group
Intervention type: OTHER
Intervention: Cross-sectional assessment
Description: Volunteers will undergo assessments, including SCID scale, SCL-90, Chinese Perceived Stress Scale(CPSS), the Measurement and Treatment Research to Improve Cognition in Schizophrenia(MATRICS) Consensus Cognitive Battery, blood test(blood routine, liver function, renal function, blood lipids, fasting blood glucose, fasting serum insulin, fasting blood glycosylated hemoglobin), as well as functional MRI, eye movement, functional near-infrared spectroscope and electroencephalogram. Blood samples for exploring difference between patients and healthy people will be collected and stored.
Study NCT06531343 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LDCT scan and simultaneous [18F]FDG PET/CT on new-generation long axial field of view scanner
Description: 18F\]FDG will be injected intravenously, and PET/CT images will be acquired after 60 minutes (± 10 minutes). PET/CT images will be first analysed with the lung window to detect any findings suggestive of a lung tumour.~Whole-body PET/CT images will be then analysed to detect any incidental finding in the chest as well as other anatomical areas included in the field of view. PET/CT images will be considered positive if there is at least one non-calcified lung nodule or any suspicious finding on CT scan characterised by focal \[18F\]FDG uptake deviating from physiological distribution or above physiological background activity.
Study NCT06531343 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LDTC only
Description: The LDCT scan will be performed in single deep inspiratory breath hold. No intravenous contrast will be administered.
Study NCT05560802 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WHOs Labour care guide
Description: Guidelines for monitoring labor progress, the WHOs LCG
Study NCT06467305 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: continuous theta-burst stimulation (cTBS)
Description: Non-invasive brain stimulation, evoked potentials and fMRI will be used to identify brain regions involved in speech motor learning and retention.
Study NCT05843695 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: iTCBT-G
Description: Group format over 2 days
Study NCT05843695 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Description: Standard care
Study NCT06467305 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptation
Description: Auditory adaptation in speech